August 7, 2025 — Leads & Copy — Trinity Biotech plc (Nasdaq: TRIB) has launched a new testing service for preeclampsia, a significant advancement in maternal health diagnostics. The service is planned to roll out in Q3 2025 through Trinity Biotech’s New York-based reference laboratory.
Trinity Biotech will offer the FDA-cleared PreClara Ratio (sFlt-1/PlGF) biomarker test as part of a strategic collaboration with Thermo Fisher Scientific, enhancing Trinity Biotech’s capabilities to deliver critical maternal health diagnostics.
Approximately 500,000 women in the United States are impacted annually by hypertensive disorders of pregnancy. The sFlt-1/PlGF test provides clinically actionable insights that support healthcare providers in making earlier, more informed decisions for hospitalized patients, enabling more targeted and timely management of care for this high-risk patient population.
Recent U.S.-based studies reinforce the clinical and economic value of the sFlt-1/PlGF test, including research published in March 2025 demonstrating potential neonatal cost savings exceeding $10 million per 1,000 patients when incorporated into standard care.
The launch lays critical groundwork for the anticipated commercial introduction of PrePsia™, Trinity Biotech’s preeclampsia risk assessment technology designed for use in early pregnancy.
Preeclampsia is a rapidly progressive hypertensive disorder affecting approximately 5-8% of pregnancies. In the United States, the condition accounts for approximately 11% of maternal deaths and 15% of premature births, with cases nearly doubling since 2007.
Contact:
Trinity Biotech plc
Gary Keating, PhD
(353)-1-2769800
RedChip Companies Inc.
Dave Gentry, CEO
(1)-407-644-4256
(1)-800-RED-CHIP (733-2447)
TRIB@redchip.com
Source: Trinity Biotech
